Published in
American Society of Hematology, Blood, 4(131), p. 397-407
DOI: 10.1182/blood-2017-09-806737
Links
Tools
A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma
Journal article published in 2017 by
Jennifer E. Amengual 
,
Renee Lichtenstein,
Jennifer Lue,
Ahmed Sawas,
Changchun Deng,
Emily Lichtenstein,
Karen Khan,
Laine Atkins,
Aishling Rada,
Hye A. Kim,
Codruta Chiuzan,
Matko Kalac,
Enrica Marchi,
Lorenzo Falchi ,
Mark A. Francescone
and other authors.
,
Renee Lichtenstein,
Jennifer Lue,
Ahmed Sawas,
Changchun Deng,
Emily Lichtenstein,
Karen Khan,
Laine Atkins,
Aishling Rada,
Hye A. Kim,
Codruta Chiuzan,
Matko Kalac,
Enrica Marchi,
Lorenzo Falchi ,
Mark A. Francescone
and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points The combination of romidepsin and pralatrexate is safe and well tolerated in patients with relapsed/refractory lymphoma. The combination led to an overall response rate of 71% (10/14, with 4/14 complete responses) in patients with relapsed/refractory T-cell lymphoma.